RÁČIL, Zdeněk, Filip RÁZGA, Jana DRÁPALOVÁ, Lucie BUREŠOVÁ, Daniela ŽÁČKOVÁ, Martina PALACKOVÁ, Lukáš SEMERÁD, Ludmila MALÁSKOVÁ, Martin HALUZÍK and Jiří MAYER. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. Haematologica. Pavia, ITALY: Ferrata Storti Foundation, 2013, vol. 98, No 10, p. "e124"-"e126", 3 pp. ISSN 0390-6078. doi:10.3324/haematol.2013.086355.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia.
Authors RÁČIL, Zdeněk (203 Czech Republic, guarantor, belonging to the institution), Filip RÁZGA (703 Slovakia), Jana DRÁPALOVÁ (203 Czech Republic), Lucie BUREŠOVÁ (203 Czech Republic, belonging to the institution), Daniela ŽÁČKOVÁ (203 Czech Republic, belonging to the institution), Martina PALACKOVÁ (703 Slovakia, belonging to the institution), Lukáš SEMERÁD (203 Czech Republic, belonging to the institution), Ludmila MALÁSKOVÁ (203 Czech Republic), Martin HALUZÍK (203 Czech Republic) and Jiří MAYER (203 Czech Republic, belonging to the institution).
Edition Haematologica, Pavia, ITALY, Ferrata Storti Foundation, 2013, 0390-6078.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Italy
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.868
RIV identification code RIV/00216224:14740/13:00069041
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.3324/haematol.2013.086355
UT WoS 000328543400001
Keywords in English Nilotinib; insulin resistance
Tags podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Olga Křížová, učo 56639. Changed: 7. 2. 2014 11:55.
Abstract
For the first time we have clarified the mechanism of impaired glucose metabolism in CML patients treated with nilotinib, which occurs via rapidly developed tissue insulin resistance and compensatory hyperinsulinemia. It also at least partially explains the fast development of dyslipidemia and probably also PAO in these CML patients. However, further studies that include a larger patient cohort, as well as in vitro tests to confirm postreceptor insulin resistance, are needed, and these are already ongoing in our study group.
Links
ED1.1.00/02.0068, research and development projectName: CEITEC - central european institute of technology
PrintDisplayed: 1. 7. 2022 04:40